PFE SEC Filings
SEC filings for PFE. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-Q | Nov 3, 2026 | 0000078003-26-000127EDGAR |
| 8-KAIPfizer's Board unanimously elected Cecile Guegan, 55, as Chief Financial Officer and Executive Vice President, effective November 1, 2026. | Nov 3, 2026 | 0000078003-26-000132EDGAR |
| 8-KAIPfizer reported Q3 2026 revenues of $16.6 billion (flat year-over-year operationally), reported diluted EPS of $0.56 and Adjusted diluted EPS of $0.87. | Nov 3, 2026 | 0000078003-26-000125EDGAR |
| 4BOURLA ALBERTChairman & CEO | Aug 12, 2026 | 0001225208-26-007083EDGAR |
| 4DAMICO JENNIFER B.SVP & Controller | Aug 6, 2026 | 0001225208-26-007004EDGAR |
| 4BLAYLOCK RONALD E | Aug 5, 2026 | 0001225208-26-006944EDGAR |
| 4Buckley Mortimer J | Aug 5, 2026 | 0001225208-26-006943EDGAR |
| 8-KAIPfizer Inc. filed an 8-K on August 4, 2026 announcing its second quarter 2026 financial results via a press release furnished as an exhibit. | Aug 4, 2026 | 0000078003-26-000094EDGAR |
| 10-QAIPfizer reports modest operational revenue growth (1% in Q2, 2% YTD) and strong performance from key products, but a GAAP pre-tax loss of $653 million in Q2 driven by impairments and legal charges. | Aug 4, 2026 | 0000078003-26-000095EDGAR |
| 8-KAIFollowing the announcement of a CFO transition, Pfizer reaffirmed its full-year 2026 financial guidance, including revenues of $59.5 to $62.5 billion and Adjusted Diluted EPS of $2.80 to $3.00. | Jun 18, 2026 | 0000078003-26-000087EDGAR |
| 8-K | Jun 18, 2026 | 0000078003-26-000085EDGAR |
| 4DAMICO JENNIFER B.SVP & Controller | Jun 10, 2026 | 0001225208-26-005911EDGAR |
| 8-KAIPfizer Inc. filed an 8-K on May 5, 2026 announcing the release of its first quarter 2026 financial results via press release. | May 5, 2026 | 0000078003-26-000053EDGAR |
| 10-Q | May 5, 2026 | 0000078003-26-000054EDGAR |
| SC 13GVanguard Capital Management | May 1, 2026 | 0002100119-26-001294EDGAR |
| 8-K | Apr 27, 2026 | 0000078003-26-000044EDGAR |
| SC 13G/AamendedThe Vanguard Group | Mar 27, 2026 | 0000102909-26-002101EDGAR |
| DEF 14A | Mar 12, 2026 | 0000078003-26-000033EDGAR |
| 4DAMICO JENNIFER B.SVP & Controller | Mar 5, 2026 | 0001225208-26-003318EDGAR |
| 4DAMICO JENNIFER B.SVP & Controller | Mar 3, 2026 | 0001225208-26-002921EDGAR |
| 4SAHNI PAYALExecutive Vice President | Feb 27, 2026 | 0001225208-26-002821EDGAR |
| 4LANKLER DOUGLAS MExecutive Vice President | Feb 27, 2026 | 0001225208-26-002820EDGAR |
| 4DAMICO JENNIFER B.SVP & Controller | Feb 27, 2026 | 0001225208-26-002819EDGAR |
| 4BOURLA ALBERTChairman & CEO | Feb 27, 2026 | 0001225208-26-002818EDGAR |
| 4Fonseca LidiaExecutive Vice President | Feb 27, 2026 | 0001225208-26-002817EDGAR |
| 4McDermott MichaelExecutive Vice President | Feb 27, 2026 | 0001225208-26-002816EDGAR |
| 4BOSHOFF CHRISTOFFELPresident, R&D | Feb 27, 2026 | 0001225208-26-002815EDGAR |
| 10-K | Feb 26, 2026 | 0000078003-26-000026EDGAR |
| 4BOSHOFF CHRISTOFFELPresident, R&D | Feb 24, 2026 | 0001225208-26-002482EDGAR |
| 4DAMICO JENNIFER B.SVP & Controller | Feb 24, 2026 | 0001225208-26-002481EDGAR |
| 8-KAIPfizer Inc. announced its financial results for the fourth quarter of 2025 via a press release dated February 3, 2026, filed under Item 2.02 of Form 8-K. | Feb 3, 2026 | 0000078003-26-000005EDGAR |
| 4BOSHOFF CHRISTOFFELPresident, R&D | Feb 2, 2026 | 0001225208-26-001126EDGAR |
| 8-K | Dec 16, 2025 | 0000078003-25-000167EDGAR |
| 8-K | Nov 21, 2025 | 0001193125-25-291406EDGAR |
| 8-K | Nov 13, 2025 | 0000078003-25-000159EDGAR |
SEC filings for companies related to PFE
Never miss a PFE filing.
Get an email when PFE files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.